Tests oral semaglutide tablets for weight loss in adults with excess weight
Compares lower doses of oral semaglutide with placebo tablets in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Key facts
- Where
- Alken, Bonheiden, Gent, Jette, and Kluisbergen, BelgiumSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity who have tried to lose weight by diet before. It tests lower doses of oral semaglutide against dummy tablets.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Body mass index (BMI) of 30.0 kg/m^2 or more, or BMI of 27.0 kg/m^2 or more with at least one weight-related health problem such as high blood pressure, abnormal blood fats, sleep apnoea or heart and blood vessel disease.
- Earlier treatment
- At least one self-reported unsuccessful diet effort to lose weight. People who have consistently used GLP-1 receptor agonists or amylin analogues before screening cannot join.
- Biomarker or test result
- HbA1c must be below 6.5% (48 mmol/mol) at screening.
Main reasons for not taking part
- Body weight changed by more than 5% in the 90 days before screening
- HbA1c of 6.5% (48 mmol/mol) or higher at screening
- Consistent use of GLP-1 receptor agonists, including dual GLP-1/GIP medicines, or amylin analogues before screening
Read by machine on 9 November 2026.
Where in Belgium
- AnimaAlken, BelgiumNo longer taking part
- ImeldaBonheiden, BelgiumNo longer taking part
- Universitair Ziekenhuis GentGent, BelgiumNo longer taking part
- UZ BrusselJette, BelgiumNo longer taking part
- KormontKluisbergen, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07770841EU 2025-524626-18-00
- Record updated
- 9 September 2026
- Original description
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.Read full original descriptionShow less
Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
Inclusion: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; Female or male (sex at birth); Age 18 years or above at the time of signing the informed consent; Body mass index (BMI) of; ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease; OR; ≥ 30.0 kg/m\^2; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: A self-reported change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records; Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment; HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.